The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in transplant-ineligible, newly diagnosed multiple myeloma. After more than 7 years ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.